IMAB (I-Mab) צמיחת רווח נקי למניה השנה

The geopolitical confrontation between the US and China limits the current international research of I-Mab (IMAB), although the long-term scale of antibody development is sustained by global outsourcing. A comparison of annual EPS growth visualizes this conflict of interest, where -179.90 expresses the latest level of the metric. The final balance is complicated by a risky business split and dependence on external financing, creating pressure on capital.

For I-Mab (IMAB), whose success depends on antibody clinical trials rather than market cycles, the current EPS YoY growth rate on the GURU.Markets platform serves as an indicator of development financial efficiency. This metric captures the percentage change in net profit per share relative to the previous year, allowing investors to assess capitalization dynamics and business model sustainability regardless of the macroeconomic backdrop.